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Summary
Background The population of patients with chronic kidney disease (CKD) is prone to high cardiovascular mor-
bidity and mortality. Aberrant circadian pattern of blood pressure is associated with increase cardiovascular risk. The 
study investigated circadian blood pressure profile in patients with early stages of CKD.
Material and methods The study included 90 patients with CKD stage 1–3, aged 34–79 years and 30 healthy 
volunteers as control group. All patients underwent ambulatory blood pressure monitoring (ABPM). Patient was 
classified as “dipper” if relative decreases in SBP and DBP at night was at least 10%. If the drop the SBP or DBP 
was less than 10% patient was classified as “non-dipper”.
Results Hypertension was present in 78.9% of patients with CKD stage 1–3. “Non-dipper” profile was found in 
59 (66%) of the surveyed patients with CKD, namely in 16 (53%) in CKD stage 1, 23 (70%) in CKD stage 2, 
and 20 (74%) in CKD stage 3. “Non-dipper” profile was observed in 9 (30%) of control patients. In the whole 
study population (n = 120) significant positive correlation was found between % drop in SBP and eGFR (r = 0.25; 
p < 0.01). There was no significant correlation between % drop in SBP and eGFR (r = 0.12; p = 0.26) in 90 CKD 
patients. There was statistically significant negative correlation between % drop in SBP and age (r = –0.25; p < 0.05) 
and BMI (r = –0.24; p < 0.05).
Conclusions “Non-dipper” profile is a common finding among patients with early stages of CKD and may be 
associated with a higher cardiovascular risk. ABPM should be a standard procedure in patients with CKD, even in 
early stages of the disease.
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Background
Blood pressure is characterized by a circadian rhythm. 
The analysis of the circadian blood pressure profile is 
possible by the-24-hour ambulatory blood pressure 
monitoring (ABP). The lowest blood pressure values 
are observed at about 3 am (between 2 and 3 am) 
and a  slight increase in blood pressure is observed 
before waking states. Then there is a sudden increase 
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in blood pressure after waking hours in the morning, 
with the highest value at about 9 o’clock and a slight 
physiological decrease of values at noon and the re-
bound in the afternoon and evening. This circadian 
rhythm occurs in people with normal blood pressure 
and in the majority of patients with essential hyper-
tension [1]. The population of patients with chron-
ic kidney disease (CKD) exhibited the presence of 
a disturbed circadian blood pressure profile — one of 
the risk factors of blood pressure related target organ 
damage [2–8]. The aim of the study was to analyse 
the circadian pattern of blood pressure in patients in 
the early stages of chronic kidney disease.
Material and methods
The study was performed between September 2012 
and November 2014, after getting the approval from 
the Bioethics Committee at the Nicolaus Copernicus 
University Collegium Medicum in Bydgoszcz. Writ-
ten consent was obtained from all patients included 
in the study.
Subjects for the research were recruited based on 
a  review of medical history of patients treated at 
the Nephrology Outpatient Clinic of the University 
Hospital No.1 in Bydgoszcz.
The study group consisted of 90 patients with 
CKD stage 1–3. Patients with diabetes were not 
included in the study group. Forty patients refused 
to participate in the study. In all subjects blood was 
sampled for serum creatinine and glomerular filtra-
tion rate (EGFR) was estimated using CKD-EPI 
equation [9]. Based on eGFR patients were classified 
as CKD stage 1 (30 patients), CKD stage 2 (33 pa-
tients) and CKD stage 3 (27 patients).
The causes of CKD in the studied patient pop-
ulation were as follows: biopsy-proven chronic glo-
merulonephritis (n = 16; 17.7%), hypertensive ne-
phropathy (n = 3; 3.3%), polycystic kidney disease 
(n = 29; 32.2%), gouty nephropathy (n = 5; 5.5%), 
nephrolithiasis (n = 23; 25.5%), history of unilateral 
nephrectomy due to pyonephrosis, trauma or tu-
mour (n = 3; 3.3%). In 11 (12.2%) cases the cause 
of CKD remained unknown.
The control group consisted of 30 individuals 
without hypertension, obesity, diabetes, CKD and 
with normal creatinine concentration in blood se-
rum.
Each patient underwent a  clinical assessment 
which included the measurement of arterial blood 
pressure (BP) and the calculation of body mass in-
dex (BMI). Systolic (SBP) and diastolic blood pres-
sure (DBP) were measured using the A&D Medical 
UA-631 automatic blood pressure monitor. Subse-
quently, mean arterial pressure (MAP) was calculated 
from the formula MAP = DBP + 1/3(SBP–DBP) 
(mm Hg) and pulse pressure (PP) was calculated 
from the formula PP = SBP–DBP (mm Hg).
 Each of the studied patients was subjected to 
24-hour ambulatory blood pressure monitoring 
(ABPM) using the A&D TM2430 device. Cuff 
size was adapted to a  patient’s  arm circumference 
and the patients were instructed on the operation 
principles of the apparatus. BP measurements 
were taken every 30 minutes. The period between 
6 am and 10 pm was considered day hours, and 
the period between 10 pm and 6 am was consid-
ered night hours. Subsequently, mean values of SBP 
and DBP from the period of the day and night 
were analysed. The percentage drop in blood pres-
sure was calculated by the following equation: 
% drop in SBP = [(SBP day – SBP night) / SBP day] 
x 100%
Similarly, % drop in diastolic blood pressure was 
calculated. If the % drop in SBP and DBP was at 
least 10% the patient was qualified as a  “dipper”, 
but if it was less than 10%, patients were classi-
fied as “non-dipper” [10]. Data on the duration of 
hypertension and antihypertensive treatment were 
obtained during the interview and from the patients’ 
charts.
Statistical analysis
The results obtained during the study were ana-
lysed statistically using the STATISTICA PL 7.0. 
For comparison of results in more than two groups 
non-parametric ANOVA test was used. Data are 
presented as mean ± standard deviation (SD). The 
level of statistical significance was set at p < 0.05.
Results
The characteristics of the study group of patients 
with CKD stage 1–3 and the control group are 
shown in the Table I.
With progress of CKD the number of “non-dip-
pers” increases (Figure 1).
Table II shows comparison of selected clinical 
parameters in patients with CKD stages 1, 2 and 3 
compared with the control group. With the progress 
of CKD the number of patients characterized by the 
feature “dipper” (p < 0.001) decreased. 
In the study hypertension was found in in 56.7% 
of patients in stage 1 CKD, in 84.9% of patients in 
stage 2 CKD and in 96.3% of patients in stage 3 
CKD. The duration of hypertension was statistical-
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Age (years) 54 ± 11 56 ± 11 0.27
Gender women/men 19/11 41/49 NS
BMI [kg/m2] 25 ± 3.1 27 ± 3.9  < 0.001
SBP ABPM [mm Hg] 123 ± 10 126 ± 14 0.15
DBP ABPM [mm Hg] 74 ± 5 76 ± 9 0.15
MAP ABPM [mm Hg] 91 ± 6 92 ± 10 0.39
PP ABPM [mm Hg] 49 ± 7 51 ± 9 0.38
SBP ABPM day [mm Hg] 131 ± 10 131 ± 14 0.99
DBP ABPM day [mm Hg] 79 ± 5 80 ± 9 0.72
MAP ABPM day [mm Hg] 96 ± 6 96 ± 11 1.00
PP ABPM day [mm Hg] 52 ± 7 52 ± 10 0.98
SBP ABPM night [mm Hg] 112 ± 12 121 ± 15  < 0.005
DBP ABPM night [mm Hg] 67 ± 7 72 ± 9  < 0.05
MAP ABPM night [mm Hg] 81 ± 8 87 ± 11  < 0.005
SBP ABPM day — SBP ABPM night (mm Hg) 18.6 ± 7.9 10.0 ± 10.5  < 0.00001
DBP ABPM day — DBP ABPM night (mm Hg) 12.4 ± 6.5 8.0 ± 10.5  < 0.005
% drop in SBP ABPM [mm Hg] 14.2 ± 5.9 8.0 ± 7.7  < 0.00001
% drop in DBP ABPM [mm Hg] 15.5 ± 7.8 10.0 ± 8.8  < 0.0002
Dippers n(%) 21(70%) 31(34%)  < 0.005
SBP [mm Hg] 132 ± 15 137 ± 15 0.18
DBP [mm Hg] 80 ± 9 84 ± 9  < 0.05
MAP [mm Hg] 98 ± 9 102 ± 9  < 0.05
eGFR CKD-EPI (ml/min/1,73 m2) 95.93 ± 15.0 74.77 ± 23.69  < 0.0001
Creatinine [mg/dl] 0.76 ± 0.20 1.06 ± 0.36  < 0.0001
Description of abbreviations listed in the table is provided in the text.
Figure 1. Prevalence of ”non-dipper” blood pressure profile in in-
vestigated groups
ly significantly higher for patients in stage 3 CKD 
when compared to patients in stage 1 and 2 of CKD 
(p < 0.001, p < 0.05, respectively). The stage of CKD 
increased number of antihypertensive medications, 
as follows: in stage one CKD median was 1.0 (range 
0–4) in stage two CKD — 1.0 (range 0–5) and in 
stage three CKD — 2.0 (range 0–5). 
In the whole population (n = 120) a  significant 
positive correlation between % drop in SBP ABPM 
and eGFR was found (r = 0.25; p < 0.01) (Figure 2)
and statistically significant negative correlations be-
tween % drop in SBP ABPM and age (r = –0.25; p < 
0.05), BMI (r = –0.30; p < 0.05). Similar correlations 
were demonstrated for the difference SBP ABPM day 
and night: a statistically significant positive correla-
tion with eGFR (r = 0.25; p < 0.01) and statistically 
significant negative correlation with age (r = –0.25; p 
< 0.01), BMI (r = –0.30; p = 0.001). In this popula-
tion a negative correlation of % drop in DBP ABPM 
with BMI (r = –0.26; p < 0.01) and negatively corre-
lated difference in DBP ABPM day and DBP ABPM 
night with BMI (r = –0.24; p < 0.01) were indicated. 
On the other hand, in 90 patients with CKD there 
was no significant correlation between GFR and % 
drop in SBP ABPM (r = 0.12; p = 0.26). However, 
arterial hypertension 2015, vol. 19, no. 4
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Age (years) 54 ± 11 50 ± 11 57 ± 11 63 ± 7  < 0.05
Gender women/men 19/11 14/16 16/17 11/16
BMI [kg/m2] 24.8 ± 3.1 26.5 ± 4.0 27.4 ± 4.07 27.8 ± 4.0 0.05
SBP ABPM [mm Hg] 123 ± 10 124 ± 11 125 ± 13 131 ± 16 0.085
DBP ABPM [mm Hg] 74 ± 5 75 ± 8 75 ± 8 77 ± 9 0.45
MAP ABPM [mm Hg] 91 ± 6 91 ± 9 90 ± 10 95 ± 11 0.28
PP ABPM [mm Hg] 49 ± 7 48 ± 6 50 ± 8 54 ± 12 0.07
SBP ABPM day [mm Hg] 131 ± 10 129 ± 12 129 ± 13 135 ± 16 0.07
DBP ABPM day [mm Hg] 79 ± 5 79 ± 10 79 ± 8 81 ± 10 0.67
MAP ABPM day [mm Hg] 96 ± 6 94 ± 12 96 ± 9 99 ± 11 0.37
PP ABPM day [mm Hg] 52 ± 7 49 ± 7 52 ± 11 54 ± 12 0.38
SBP ABPM night [mm Hg] 112 ± 12 117 ± 12 120 ± 15 127 ± 17  < 0.001
DBP ABPM night [mm Hg] 67 ± 7 71 ± 8 70 ± 10 74 ± 9  < 0.05
MAP ABPM night [mm Hg] 81 ± 8 86 ± 9 86 ± 11 91 ± 11  < 0.001
SBP ABPM day — SBP ABPM night [mm Hg] 18.6 ± 7.9 11.6 ± 11.1 9.9 ± 10.7 8.3 ± 9.6  < 0.001
DBP ABPM day — DBP ABPM night [mm Hg] 12.4 ± 6.5 8.2 ± 8.4 8.8 ± 6.4 7.5 ± 7.9 0.052
% drop in SBP ABPM [mm Hg] 14.2 ± 5.9 8.7 ± 8.2 7.6 ± 7.9 6.1 ± 7.1  < 0.0001
% drop in DBP ABPM [mm Hg] 15.5 ± 7.8 9.8 ± 9.8 11.1 ± 7.9 8.8 ± 8.9  < 0.05
Dippers n(%) 21(70%) 14(47%) 10(30%) 7(26%)  < 0.001
SBP [mm Hg] 132 ± 15 136 ± 14 135 ± 14 141 ± 16 0.17
DBP [mm Hg] 80 ± 9 86 ± 9 83 ± 10 84 ± 6 0.07
MAP [mm Hg] 98 ± 9 103 ± 10 100 ± 9 103 ± 8 0.11
PP [mm Hg] 52 ± 13 50 ± 9 51 ± 13 58 ± 15 0.16
eGFR CKD-EPI [ml/min/1,73 m2] 95.93 ± 15.0 101.42 ± 9.45 74.47 ± 8.98 46.36 ± 8.07  < 0.0001
Creatinine [mg/dL] 0.76 ± 0.20 0.75 ± 0.17 0.99 ± 0.16 1.47 ± 0.29  < 0.0001
Description of abbreviations listed in table is provided in the text.
Figure 2. Correlation between % drop in SBP ABPM and eGFR (CKD-EPI)
statistically significant negative correlation was found 
between % drop in SBP ABPM: age (r = –0.25; p < 
0.05), BMI (r = –0.24; p < 0.05).
In multivariate analysis % drop in SBP ABPM is 
significantly correlated with age (r = 0.049), BMI 
(r = 0.039), eGFR (r = 0.844). Multiple analytical 
results are shown in Table III.
Discussion
In recent years, ambulatory blood pressure monitor-
ing (ABPM) was widely used in diagnosing patients 
with hypertension. Blood pressure values obtained by 
ABPM, better than casual measurements, correlate 
with organ damage of hypertension [11–13]. With 
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the twenty-four hour blood pressure monitoring it has 
become possible to analyse the circadian blood pressure 
profile.
CKD is a syndrome which on one hand increases 
the morbidity and mortality of cardiovascular disease 
[14] and on the other hand the presence of other 
cardiovascular diseases accelerates the progression 
of renal disease [15]. Complications of the cardio-
vascular system are the leading cause of death in 
the population of CKD patients [14, 16]. The high 
morbidity and cardiovascular mortality in chronic 
kidney disease is due to the accumulation of cardio-
vascular risk factors. Among these factors, tradition-
al factors such as inter alia hypertension, diabetes, 
smoking and non-traditional factors associated with 
the progression of CKD are mentioned. To the latter 
group among other factors, chronic inflammation, 
hypervolemia, oxidative stress, elevated levels: asym-
metric dimethylarginine, parathyroid hormone, en-
dothelin, homocysteine, and excessive activity of the 
sympathetic nervous system are included [17, 18]. 
In the present study hypertension as a risk factor for 
increased morbidity and mortality of cardiovascu-
lar disease concerned 78.9% of patients with CKD 
stages 1–3.
As already mentioned, the ambulatory blood pres-
sure monitoring is used in assessing cardiovascular 
risk due to the ability to analyse the profile of pres-
sure circadian rhythm. Among patients with kidney 
disease there is a tendency to lack of nocturnal fall 
in blood pressure [19]. The results of this study in-
dicate the presence of “non-dipper” profile in 66% 
of patients with chronic kidney disease stage 1–3. 
In this group, 57% had hypertension. In other stud-
ies, the percentage of patients with CKD stage 1–3 
in whom a “non-dipper” profile was determined is 
equal to 41–46% [7, 8], and 41–78.5% of patients 
with eGFR < 60 ml/min/1.73 m2 [5, 20–22]. In the 
group of untreated patients immediately after the 
diagnosis of primary chronic glomerulonephritis an 
abnormal circadian rhythm was found in 70% of 
patients [23]. In the present study a  “non-dipper” 
profile was indicated in 30% of the control group. 
In other works this percentage ranged from 17% to 
57% [24, 25]. There are many reasons that can be 
responsible for the presence of the disadvantageous 
“non-dipper” profile in the population of patients 
with CKD. These can be, among others, the in-
creased activity of the sympathetic nervous system as 
a result of impulses from afferent fibres innervating 
the kidney, water balance disorders, disturbances in 
the secretion of adrenal hormones as well as paren-
chymal kidney damage [19, 26–29].
Regardless of the mechanism of disorders in the 
circadian rhythm of blood pressure, patients without 
a  nocturnal drop in pressure are characterized by 
a higher incidence of organ complications [30, 31]. 
Patients with chronic kidney disease despite good 
control of blood pressure during the day may be at 
risk for cardiovascular complications caused by night 
hypertension [32].
Ishikawa et al. during 41 months observed 811 
patients over 60 years old with hypertension includ-
ing: 537 with CKD and 274 without CKD [5]. 
Analysing the circadian blood pressure profile they 
distinguished: “non-dippers”, “dippers” and “extreme 
dippers” (extreme dippers been defined as an indica-
tor of the SBP pressure measured during sleep/SBP 
measured at the time of the activity of < 0.8). They 
showed that patients with CKD during observation 
regardless of whether the circadian rhythm was chara - 
cteristic for “dippers” or “non-dippers” were sad-
dled with an increased risk of cardiovascular events 
(non-dippers: hazard ratio [HR], 2.16; 95% con-
fidence interval [CI], 1.19–3.91; extreme dippers: 
HR, 2.38; 95% CI, 1.17–4.83). Patients with CKD 
were characterized by an increased risk of cardiovas-
cular events. Ishikawa et al. thought that CKD and 
other cardiovascular risk factors explain the increased 
risk in patients characterized as “non-dippers”, but 
do not explain the increased risk in the group of 
“extreme dippers”. In turn, another group of re-
search [33] examining patients with CKD stage 1–4 
which constituted of 38% of patients with diabetes 
and 83% with dyslipidaemia demonstrated that the 
group of patients with CKD stage 3–4 was charac-
terized by more frequent occurrence of disturbed 
circadian rhythms than those in the initial stage of 
CKD (p = 0.018). The authors found out that CKD 
is the only feature that significantly affects the circa-
dian blood pressure profile in the study group. The 
“non-dipper’’ profile of blood pressure in patients 
with CKD is associated with a hazard ratio of 2.5 for 
cardiovascular events and 9.6 for death from these 
causes [34].
Table III. Results of multiple linear regression analysis with % 
drop in SBP ABPM as a dependent variable (Model 1)
Model 1
R = 0.33; R2 = 0.11; Adjusted R2 = 0.079
F = 3.53; p < 0.02
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The presence of “non-dipper’’ profile of blood 
pressure and left ventricular hypertrophy are pre-
disposing factors for the development of CKD in 
patients with hypertension, without diabetes [7, 35]. 
This indicates a  need to monitor the condition of 
heart and blood pressure circadian profile as soon as 
diagnosis of chronic renal disease is made, especially 
if the patient is hypertension. In the population of 
patients with hypertension in which the “non-dip-
per’’ profile of blood pressure feature dominates, 
especially if the eGFR is < 60 ml/min/1.73 m2 phar-
macologic therapy is vitally important [21]. It aims 
to reduce the risk of cardiovascular complications 
associated with uncontrolled blood pressure values 
and the consequences of impaired circadian rhyme. 
The action of the ACE inhibitor and the angiotensin 
receptor blocker apart from their antihypertensive 
activity exhibit a nephroprotective effect. Moreover, 
in a  population of patients with CKD they par-
tially block the sympathetic nervous system which 
is responsible for the disadvantageous “non-dipper’’ 
profile [36]. No drop in blood pressure at night may 
be a consequence of an autonomic dysfunction in the 
early stages of CKD.
Statistically significant positive correlation be-
tween % drop in SBP ABPM and eGFR (r = 0.25; 
p < 0.01) demonstrated in this study for the general 
population (n = 120) may indicate the significance 
of deterioration of renal function on the normal reg-
ulation of blood pressure. Luck of this dependence 
in patients with CKD can be explained by reduced 
number of patients enrolled in the study, but may 
also result from failure to analyse patients with more 
advanced CKD (stage 4 and stage 5).
In the multivariate analysis of the % drop in SBP 
ABPM age, BMI and eGFR were analysed as inde-
pendent variables. This model explained only 11% of 
the variability of % drop in SBP ABPM. This means 
that the variability of this feature is dependent on 
many factors which are not analysed in the present 
study. These factors include the concentration of al-
bumin in the blood serum, proteinuria, activation of 
the sympathetic nervous system [22, 37, 38].
It must be concluded that the vast majority of 
patients with stage 1–3 CKD is characterized by 
“non-dipper’’ profile. Data from recent years show 
that patients with hypertension characterized as 
“non-dippers” are burdened with a higher risk of car-
diovascular events [13]. Evaluation of circadian blood 
pressure profile may identify CKD patients at high 
risk of complications of the cardiovascular system.
Conclusions
“Non-dipper” profile is a  common finding among 
patients in the early stages of CKD and may be 
associated with a higher cardiovascular risk. ABPM 
should be a  standard procedure in patients with 
CKD, even in early stages of the disease.
Streszczenie
Wstęp Populacja chorych z CKD charakteryzuje się wysoką chorobowością i śmiertelnością sercowo-naczyniową. Ta grupa 
pacjentów charakteryzuje się zaburzonym dobowym profilem ciśnienia tętniczego, a cecha ta może zwiększać ryzyko ser-
cowo-naczyniowe. Celem pracy była analiza dobowego rytmu ciśnienia tętniczego u pacjentów we wczesnych stadiach CKD. 
Materiał i metody Badaniem objęto 90 chorych w 1–3 stadium CKD w wieku 34–79 lat oraz 30 osób w wieku 38–79 
lat stanowiących grupę kontrolną. U wszystkich badanych przeprowadzono ambulatoryjne monitorowanie ciśnienia tęt-
niczego (ABPM). Jeśli względne obniżenie SBP i DBP w nocy wynosiło co najmniej 10% pacjenta kwalifikowano jako 
„dipper”, natomiast jeśli spadek SBP i DBP był mniejszy niż 10% pacjenta kwalifikowano jako „non-dipper”.
Wyniki Nadciśnienie tętnicze występowało u 78,9% pacjentów z CKD w stadium 1–3. Profil „non-dipper” stwier-
dzono u 59 (66%) spośród badanych chorych z CKD, w tym w stadium 1 CKD u 16 (53%), w stadium 2 CKD 
u 23 (70%) oraz u 20 (74%) w stadium 3 CKD. W grupie kontrolnej profil non-dipper stwierdzono u 9 (30%) 
pacjentów. W badanej całej populacji (n = 120) stwierdzono znamienną statystycznie dodatnią korelację między % 
spadkiem SBP i eGFR (r = 0,25; p < 0,01). W grupie 90 pacjentów z CKD nie wykazano korelacji między eGFR 
% spadkiem SBP (r = 0.12; p = 0.26). Występowały natomiast znamienne statystycznie ujemne korelacje % spadku 
nocnego SBP z: wiekiem (r = –0,25; p < 0,05) oraz BMI (r = –0,24; p < 0,05).
Wnioski Wśród pacjentów z  CKD w stadium 1–3 częściej występuje cecha “non-dipper” co może się wiązać 
z wyższym ryzykiem incydentów sercowo-naczyniowych w tej grupie chorych. ABPM powinno być standardowym 
postępowaniem u pacjentów z CKD, nawet w jej wczesnych stadiach.
słowa kluczowe: przewlekła choroba nerek, dipper, non-dipper, dobowy profil ciśnienia tętniczego
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